Our pipeline includes Tissue-Specific Therapeutics and Tissue-Specific Biologics
for soft tissue sarcoma, colorectal cancer, and inflammatory bowel disease. Our collaboration with BeiGene includes a planned combination clinical trial with our lead candidate, IMX-110.
Our lead candidate IMX-110 for soft tissue sarcoma is currently in clinical trials as a monotherapy, and is planned to be combined with tislelizumab (BeiGene anti-PD-1) for advanced solid tumors. IMX-111 and IMX-120 clinical trials are planned in oncology and inflammation, respectively.
